Cel-Sci
CVM
C$11.83
Share price
5.00%
Change (1 day)
588.41%
Change (1 year)
Categories
Cel-Sci (CVM) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : C$18.97 Million
According to Cel-Sci 's latest financial reports the company's total liabilities are C$18.97 Million. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Cel-Sci - Total liabilities on balance sheet (from 2001 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-09-30 | C$19.1 M | -18.8% |
| 2023-09-30 | C$23.52 M | -6.99% |
| 2022-09-30 | C$25.29 M | 3.15% |
| 2021-09-30 | C$24.52 M | -11.42% |
| 2020-09-30 | C$27.68 M | -7.03% |
| 2019-09-30 | C$29.78 M | -21.61% |
| 2018-09-30 | C$37.98 M | 16.62% |
| 2017-09-30 | C$32.57 M | -3.19% |
| 2016-09-30 | C$33.65 M | -24.15% |
| 2015-09-30 | C$44.36 M | 350.58% |
| 2014-09-30 | C$9.84 M | 130.47% |
| 2013-09-30 | C$4.27 M | -51.98% |
| 2012-09-30 | C$8.89 M | -10.09% |
| 2011-09-30 | C$9.89 M | -3.53% |
| 2010-09-30 | C$10.25 M | -74.56% |
| 2009-09-30 | C$40.32 M | 885.76% |
| 2008-09-30 | C$4.09 M | -31.95% |
| 2007-09-30 | C$6.01 M | -49.14% |
| 2006-09-30 | C$11.81 M | 921.98% |
| 2005-09-30 | C$1.15 M | -34.08% |
| 2004-09-30 | C$1.75 M | -22.83% |
| 2003-09-30 | C$2.27 M | -46.83% |
| 2002-09-30 | C$4.27 M | 433.26% |
| 2001-09-30 | C$0.8 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Curis CRIS | C$63.09 M | 232.62% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | C$1.28 B | 6,648.79% | 🇺🇸 USA |
 Amgen AMGN | C$114.23 B | 602,094.14% | 🇺🇸 USA |
 Xencor XNCR | C$0.36 B | 1,817.63% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | C$44.15 B | 232,681.78% | 🇮🇱 Israel |
 Johnson & Johnson JNJ | C$158.74 B | 836,729.72% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | C$1.19 B | 6,224.63% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | C$15.12 M | -20.28% | 🇺🇸 USA |